In the competing risk analysis, patients with high serum myostatin also had a significantly higher risk of HCC development than those with low serum myostatin (HR 6.80, 95% CI 4.20–10.97, p < 0.001). The gene discussed is MSTN; the disease is hepatocellular carcinoma.